DYN
Dyne Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.28
−2.69%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.88
- Revenue estimate
- —
Latest reported
- Last report date
- Jul 30, 2026
- EPS actual
- -$1.08
- EPS estimate
- -$0.75
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -13.0%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $40
- PT range
- $35 – $45
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026